Kenji Nakamura

Bureau: Tokyo

An elderly patient's hand resting on the rail of an infusion chair beside a slow IV drip, soft clinical light, a PET scan glowing faintly on a wall monitor.

Life

Cochrane Pools 17 Trials and 20,000 Patients — Finds Anti-Amyloid Effect Absent or Trivial

Twenty thousand patients, seventeen trials, three decades, one consensus instrument — and the effect on what it feels like to lose a mind is absent or trivial.

By Kenji Nakamura, Tokyo April 18 5 min read

A quiet research laboratory at night with a sequencing machine running, blue-green light on pipettes, a closed binder labeled draft guidance

Technology

FDA Writes the First Standard for CRISPR Safety, and the Rare-Disease Pathway Follows

The FDA's April 15 draft guidance is the first standardized safety framework for CRISPR, base-editing, and prime-editing therapies, paired with a rare-disease pathway modeled on Baby KJ.

By Kenji Nakamura, Tokyo April 18 2 min read